Anti-epileptic drugs Medicine Grade Pharma Intermediate Hot sale Powder Tablets CAS 148553-50-8

                                                      CAS 148553-50-8 Usage:

              CAS 148553-50-8 is an analog of the neurotransmitter gamma-aminobutyric acid (GABA), sold under the trade name. In December 2004, the FDA approved CAS 148553-50-8 as a drug for the treatment of diabetic neuralgia and herpes zoster neuralgia.CAS 148553-50-8 is the first drug approved by in the United States and Europe for the treatment of the above two types of pain. In June 2005, CAS 148553-50-8 was approved for adjuvant treatment of adult partial-onset epilepsy. In March 2006, the European Union approved CAS 148553-50-8 for the treatment of generalized anxiety disorder (GAD) and social anxiety disorder (SAD).
              
             CAS 148553-50-8 is mainly used for the treatment of peripheral neuralgia and adjuvant treatment of localized partial seizures.
             CAS 148553-50-8 may reduce the calcium-dependent release of some neurotransmitters by modulating calcium channel function. Although CAS 148553-50-8 is a structural derivative of the inhibitory neurotransmitter γ-aminobutyric acid (GABA), it does not directly bind to GABAA, GABAB, or benzodiazepine receptors and does not increase GABAA in cultured neurons Response, did not change the concentration of GABA in the brain of rats, and had no acute effect on the uptake or degradation of GABA. However, the study found that prolonged exposure of cultured neurons to CAS 148553-50-8 increased the density of GABA transporters and the rate of functional GABA transport. CAS 148553-50-8 does not block sodium channels, has no activity on opioid receptors, does not alter cyclooxygenase activity, has no activity on dopamine and serotonin receptors, and does not inhibit the reactivation of dopamine, serotonin, ingest.